Waystar Holding Corp. research snapshot
WAY AI stock analysis currently reads Waystar Holding Corp. as a cloud-based healthcare payment software and revenue cycle management (RCM) platform that processes millions of patient transactions daily for hospitals, physician groups, and health systems. The stock closed at $22.43 on July 10, 2026, with a calculation-verified market capitalization of about $4.30 billion. WAY has declined roughly 46% from its 52-week high of $41.47 as the market repriced healthcare technology names amid AI disruption fears and margin concerns. However, the business generated $1.16 billion in TTM revenue, $126.1 million in GAAP net income, and $327.65 million in levered free cash flow. The main tension is between a cash-generating RCM platform at a reasonable free-cash-flow multiple and a stock that has lost nearly half its value in a year. This page uses scenario analysis, not a certain price prediction, and is informational, not investment advice.
Current price
$22.43
Market cap
$4.30 billion
AI score
48 / 100
Rating
Healthcare payment technology with solid cash flow, near 52-week low
Trend status
Significant decline from 52-week high, near the bottom of the range
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Waystar provides cloud-based healthcare RCM and payment software that processes patient transactions for providers. Revenue is recurring and backed by long-term contracts, but the business is still scaling toward durable operating leverage. | Medium-high |
| Moat | The moat comes from provider switching costs, integration depth with EHR and practice management systems, regulatory compliance requirements, and transaction-processing scale. It is real but not absolute, because large health systems can build or buy competing capability. | Medium |
| Management | CEO Matt Hawkins and the Waystar leadership team have navigated the IPO process, built a scaled RCM platform, and generated positive cash flow. The key test is whether management can sustain growth and margin expansion as AI-native tools enter the market. | Medium |
| Financial trend | TTM revenue is approximately $1.16 billion, GAAP net income is $126.1 million, and levered free cash flow is $327.65 million. The company is GAAP-profitable with strong cash conversion, but debt and slowing growth expectations have weighed on the stock. | High |
| Valuation | At $22.43, financial_rigor.py verifies about 33.5x P/E, 1.09x book value, 13.1x levered FCF, and 3.65x TTM revenue. The FCF multiple is reasonable for a cash-generating healthcare tech platform, but the P/E and revenue multiples leave limited room for error if growth slows. | Medium |
| Technical trend | WAY trades near the bottom of its 52-week range after a prolonged downtrend. The stock is below its 50-day and 200-day moving averages, reflecting sustained selling pressure. | Medium |
| Risk level | Risk is medium-high. The stock faces AI disruption narrative risk, customer concentration, healthcare regulation, debt leverage, potential slower growth, and the uncertainty of a recently public company with limited public earnings history. | High |
| AI confidence | Descriptive confidence is high because public filings are available and the cash flow data is verifiable. Forward-return confidence is lower because the steep decline suggests the market sees risks that may not be fully visible in the financial statements. | High data confidence |
| Investment certainty | Waystar is easier to understand as a cash-flowing healthcare RCM platform than to assess for margin of safety at the current price. The stock needs either a catalyst or time to prove that the selloff was overdone. | Medium-low |
WAY AI stock forecast
The WAY AI stock forecast should be read as a scenario range, not a price promise. Using a July 10, 2026 price of $22.43, TTM diluted EPS of $0.67, and financial_rigor.py three-year assumptions, the tested intrinsic-value outputs are roughly $32.40 bullish, $18.80 base, and $8.80 bearish. These are hypothetical ranges, not guarantees.
$30 to $34
More likely if Waystar sustains 20% annual EPS growth through organic RCM adoption, margin expansion, and cross-selling, while the market applies a 28x P/E multiple in line with profitable healthcare tech peers and the AI disruption narrative fades.
$17 to $20
More likely if Waystar grows EPS at roughly 12% annually, margins improve modestly, but the P/E multiple compresses to around 20x as the market remains cautious on healthcare IT spending and competitive pressure from AI billing tools.
$8 to $10
More likely if growth slows to 3% or less, customer churn increases due to AI-native competition, debt service limits investment, or the market assigns a distressed 12x multiple to declining earnings power.
WAY AI technical analysis
WAY AI technical analysis is bearish-biased as of the July 10, 2026 data cutoff. The stock trades near $22.43, well below both its 50-day and 200-day moving averages, and near the lower end of its 52-week range of $17.26 to $41.47. The technical picture suggests sustained distribution but does not rule out a mean-reversion bounce from oversold levels.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $22.43 | Quote used for this static page and market-cap verification around the July 10, 2026 data cutoff. |
| Near support | $20 to $21 | Psychological round-number zone. A decisive close below $20 would open the path toward the 52-week low. |
| 52-week low | $17.26 | The stock established this low during the selloff. A test of this level matters for measuring downside extension. |
| Near resistance | $25 to $27 | Former support zone that may act as resistance on any bounce. A close above $27 would be the first sign of trend improvement. |
| 50-day moving average | Requires live chart confirmation | The stock trades below it. A reclaim of the 50-day would be a short-term bullish signal but needs volume confirmation. |
| 200-day moving average | Requires live chart confirmation | WAY is well below the long-term average. Regaining the 200-day would require a sustained rally, not just a dead-cat bounce. |
| Momentum | Bearish and oversold risk | Downside momentum is strong. Oversold bounces are possible but should be traded with tight risk controls. |
| Volume | Monitor for accumulation | Below-average volume on up days and above-average on down days would confirm distribution. Look for the opposite pattern as a reversal signal. |
| Volatility | Elevated monitoring priority | WAY has high volatility for a healthcare IT stock due to AI disruption headlines, macro rotation, and its relatively small public float. |
| Invalidation | Close below $17 | A close below the 52-week low of $17.26 would invalidate the mean-reversion setup and suggest a new leg of downside. |
WAY AI trading strategy
The WAY AI trading strategy below is a rules-based framework for scenario planning and risk control, not personal advice. It connects price action with RCM adoption data, customer renewal trends, healthcare IT spending, and AI competitive landscape developments.
If WAY pulls back toward the $17 to $20 zone without a fundamental break (no major customer loss, no debt covenant breach), compare price stabilization with FCF trends, customer count, and renewal rates. A reversal candle pattern with above-average volume near support can be studied.
Do not average down. The setup invalidates if the stock closes below $17 and stays there. Define the maximum position size before entry.
Watch for WAY to reclaim and hold above $25 to $27 with volume confirmation before considering a trend-based entry. Pair the signal with improving EPS guidance, FCF growth, or positive analyst revisions.
A failed breakout back below $25 or a close below the 50-day moving average can be used as a rules-based stop point.
Track quarterly revenue growth, EPS, levered FCF, customer count and retention, enterprise contract value, net debt, and AI competitive developments. WAY reports earnings around late July 2026, which is a key catalyst.
The stock can gap significantly on earnings, AI headlines, or healthcare policy changes. Use wider position bands during earnings season.
Investment research summary
Waystar sells cloud-based software that helps healthcare providers get paid faster and more accurately. Customers, including hospitals, physician groups, and health systems, pay because the platform reduces denied claims, streamlines patient payments, and automates revenue cycle processes that were previously manual and error-prone.
The moat comes from integration depth with EHR/practice management systems, provider switching costs, regulatory compliance requirements, and transaction scale. It is real because replacing a deeply embedded RCM platform is disruptive and costly for a health system. It is not absolute because large providers can build or buy competing RCM tools, especially as AI reduces the cost of building billing automation.
The thesis fails if AI-native billing tools make Waystar RCM platform obsolete, if large health systems bring payments processing in-house, if customer churn accelerates due to price competition, if debt service constrains investment in growth, or if the stock decline reflected real fundamental deterioration that has not yet appeared in financial statements.
CEO Matt Hawkins has led Waystar through its IPO, built a platform processing significant transaction volume, and delivered positive GAAP net income and strong FCF. The key question is whether management can sustain growth and adapt the platform as AI reshapes healthcare billing, while managing debt and maintaining margins.
Healthcare RCM benefits from the secular shift toward value-based care, outpatient migration, consumerization of healthcare payments, and the growing complexity of insurance billing. However, the same trends attract competition from AI-native startups, EHR vendors adding RCM modules, and large health IT consolidators.
At about $4.30 billion in verified market value and $5.63 billion enterprise value, WAY trades at roughly 13.1x levered FCF, which is not expensive for a cash-generating software platform. The margin of safety depends on whether current earnings power is sustainable or whether the market is correctly anticipating earnings erosion from competition and slowing growth.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| WAY price | $22.43 | Yahoo Finance close on July 10, 2026 | July 12, 2026 |
| Market capitalization | $4.30 billion, verified from $22.43 x 191.78M shares | Yahoo Finance and financial_rigor.py verification | July 12, 2026 |
| Enterprise value | $5.63 billion | Yahoo Finance statistics | July 12, 2026 |
| TTM revenue | $1.16 billion | Yahoo Finance financials | July 12, 2026 |
| GAAP net income (TTM) | $126.1 million | Yahoo Finance income statement | July 12, 2026 |
| Diluted EPS (TTM) | $0.67 | Yahoo Finance statistics | July 12, 2026 |
| Levered free cash flow (TTM) | $327.65 million | Yahoo Finance cash flow | July 12, 2026 |
| Cash and equivalents | $160.13 million | Yahoo Finance balance sheet | July 12, 2026 |
| 52-week range | $17.26 to $41.47 | Yahoo Finance statistics | July 12, 2026 |
| Valuation math | 33.5x P/E, 13.1x P/FCF, 3.65x P/S, 1.09x P/B | financial_rigor.py verification | July 12, 2026 |
This WAY AI stock analysis is for informational and educational use only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 12, 2026 and can be wrong if fundamentals, competition, healthcare regulation, debt markets, AI technology shifts, or investor sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
